BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Sells $10,583,166.30 in Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Healthcare Master Fun Broadfin sold 1,793,757 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $5.90, for a total value of $10,583,166.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Friday, November 15th, Healthcare Master Fun Broadfin sold 2,206,243 shares of BioDelivery Sciences International stock. The stock was sold at an average price of $6.04, for a total value of $13,325,707.72.

BDSI stock traded up $0.06 during midday trading on Tuesday, hitting $6.15. 3,038,600 shares of the company traded hands, compared to its average volume of 959,508. BioDelivery Sciences International, Inc. has a twelve month low of $2.80 and a twelve month high of $6.45. The company has a quick ratio of 2.02, a current ratio of 2.25 and a debt-to-equity ratio of 0.86. The business has a 50 day simple moving average of $5.38 and a 200-day simple moving average of $4.62. The stock has a market capitalization of $550.57 million, a price-to-earnings ratio of -8.42 and a beta of 0.39.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.34. BioDelivery Sciences International had a negative return on equity of 8.80% and a negative net margin of 22.11%. The company had revenue of $30.31 million for the quarter, compared to the consensus estimate of $28.86 million. Equities research analysts forecast that BioDelivery Sciences International, Inc. will post 0.02 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in shares of BioDelivery Sciences International by 3.8% in the third quarter. Russell Investments Group Ltd. now owns 86,390 shares of the specialty pharmaceutical company’s stock valued at $365,000 after acquiring an additional 3,160 shares during the period. Rhumbline Advisers boosted its position in shares of BioDelivery Sciences International by 4.6% in the third quarter. Rhumbline Advisers now owns 87,670 shares of the specialty pharmaceutical company’s stock valued at $369,000 after acquiring an additional 3,851 shares during the period. BTR Capital Management Inc. bought a new stake in shares of BioDelivery Sciences International in the second quarter valued at approximately $47,000. Cutter & CO Brokerage Inc. bought a new stake in shares of BioDelivery Sciences International in the second quarter valued at approximately $60,000. Finally, NEXT Financial Group Inc boosted its position in shares of BioDelivery Sciences International by 17.0% in the second quarter. NEXT Financial Group Inc now owns 135,350 shares of the specialty pharmaceutical company’s stock valued at $629,000 after acquiring an additional 19,700 shares during the period. 68.20% of the stock is owned by institutional investors.

Several equities analysts have commented on the company. BidaskClub upgraded BioDelivery Sciences International from a “buy” rating to a “strong-buy” rating in a report on Saturday. William Blair reiterated a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 17th. Janney Montgomery Scott reiterated a “buy” rating on shares of BioDelivery Sciences International in a report on Wednesday, November 13th. LADENBURG THALM/SH SH increased their price target on BioDelivery Sciences International from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, ValuEngine upgraded BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $6.50.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Bid-Ask Spread

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.